TB-500 (Thymosin Beta-4)
researchSystemic healing peptide for tissue repair, inflammation reduction, and recovery
Availability in Thailand
TB-500 is available from Thai peptide vendors with domestic shipping. It is offered at select clinics in Bangkok and Pattaya as part of healing and recovery programs, often sold alongside BPC-157 as the 'Wolverine Stack' combination.
Prescription: Not required from vendors. Some clinics include it in supervised recovery protocols.
Legal status: Available as a research peptide. Not an approved pharmaceutical in any country.
Where to Buy in Thailand
TB-500 pricing varies by vial size (typically 5mg or 10mg). Often purchased alongside BPC-157 for the Wolverine Stack combination. Check vendor and clinic websites for current rates.
Vendors
Bangkok Health
Bangkok
Meditech peptides and performance compounds with domestic shipping
View vendor →Clinics
Overview
TB-500 is a synthetic version of thymosin beta-4, a naturally occurring 43-amino acid protein found in high concentrations in platelets, wound fluid, and most mammalian cells. It plays a fundamental role in actin regulation — the process that controls cell movement, shape, and division. This makes TB-500 uniquely effective for systemic healing: it helps cells migrate to injury sites throughout the body, promotes new blood vessel formation, and reduces inflammation and scarring.
How It Works
Actin regulation and cell migration
TB-500's core mechanism is binding G-actin monomers and modulating cytoskeletal dynamics. This enables cells to migrate efficiently to injury sites — a critical step in all tissue repair. Cells cannot heal what they cannot reach, and TB-500 removes this bottleneck by enhancing cellular mobility throughout the body.
Angiogenesis
TB-500 promotes the formation of new blood vessels, increasing blood flow, oxygen delivery, and nutrient transport to damaged tissue. In wound healing studies, thymosin beta-4 treatment increased re-epithelialisation by 42% at 4 days and up to 61% at 7 days post-wounding, with significantly increased collagen deposition.
Anti-inflammatory and anti-fibrotic effects
TB-500 reduces excessive inflammatory cell infiltration in wounds, creating an environment that favours repair over chronic inflammation. It also promotes more organised, mature collagen fibre formation — resulting in reduced scarring compared to untreated healing.
Systemic distribution
Unlike peptides that require local injection near the injury, TB-500 distributes throughout the body regardless of injection site. It upregulates healing at all active injury sites simultaneously, which is why injection location does not need to match the injury location.
Protocol Quick Reference
Benefits & Uses
- Systemic tissue repair: Promotes healing across muscle, tendon, ligament, cardiac, and neurological tissue — works body-wide from any injection site
- Wound healing acceleration: Preclinical studies showed 42-61% faster wound closure with improved collagen quality and reduced scarring
- Inflammation reduction: Reduces excessive inflammatory response while supporting the beneficial aspects of healing inflammation
- Complements BPC-157: The 'Wolverine Stack' — TB-500 handles systemic healing and cell migration while BPC-157 provides local tissue repair and angiogenesis through complementary pathways
- Flexibility and joint health: Users commonly report improved flexibility and reduced joint stiffness, likely from enhanced tissue repair and reduced inflammation
- Cardiovascular support: Research in cardiac tissue models shows potential for post-ischaemic repair and improved vascular function
Side Effects
Common
- Water retention / bloating — most common during the loading phase, typically temporary
- Headaches — sometimes reported in the first 1-2 weeks, usually resolve as the body adjusts
- Mild fatigue — transient, especially during loading phase
- Lightheadedness after injection
Less Common
- Nausea — rare and usually mild
- Flushing or warmth
Serious
- Angiogenesis caution — TB-500 promotes blood vessel growth, so it should be avoided by individuals with active cancer or a history of cancer, as it could theoretically support tumour vascularisation
- Long-term human clinical data is limited — most evidence is preclinical
- Immunomodulatory effects — thymosin beta-4 is involved in immune regulation; long-term effects beyond 6 months are not fully characterised
- Banned by WADA — athletes subject to anti-doping testing must avoid
- A Phase I/II trial of intravenous thymosin beta-4 at doses far above standard subcutaneous protocols (42-1,260 mg) showed it was well tolerated with minimal toxicity
Related Peptides
FAQ
What is the Wolverine Stack?▼
The Wolverine Stack is the popular combination of BPC-157 and TB-500, named for the comic book character's healing abilities. BPC-157 provides localised tissue repair and angiogenesis, while TB-500 handles systemic healing and cell migration. They work through complementary pathways and are commonly used together for 4-8 weeks for accelerated recovery from injuries.
Do I need to inject TB-500 near my injury?▼
No. TB-500 is systemically active and distributes throughout the body regardless of injection site. Unlike BPC-157, which benefits from local injection, TB-500 works body-wide from a standard subcutaneous injection in the abdomen, thigh, or upper arm.
Can I mix TB-500 and BPC-157 in the same syringe?▼
No — inject them separately. They should not be mixed in the same syringe. You can inject both in the same session, just use separate syringes and different injection sites.
Why does TB-500 use a loading phase?▼
TB-500 needs to reach systemic saturation to be effective — it works throughout the entire body, not just locally. The loading phase (higher doses for 4-6 weeks) builds tissue concentration body-wide, after which a lower maintenance dose sustains those levels.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.